# Suprafascial Vancomycin Powder for Prevention of Surgical Site Infections After Instrumented Posterior Spinal Fusion

> **NCT04017468** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 450 (estimated)

## Conditions studied

- Surgical Site Infection

## Interventions

- **DRUG:** Vancomycin

## Key facts

- **NCT ID:** NCT04017468
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-15
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-03-31
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2025-07-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04017468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04017468, "Suprafascial Vancomycin Powder for Prevention of Surgical Site Infections After Instrumented Posterior Spinal Fusion". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04017468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*